Aspirin versus placebo on estrogen levels in postmenopausal women: a double-blind randomized controlled clinical trial.
Estradiol
Non-steroidal anti-inflammatory agents
Postmenopause
Sex hormone-binding globulin
Testosterone
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
17 05 2022
17 05 2022
Historique:
received:
21
10
2021
accepted:
13
05
2022
entrez:
17
5
2022
pubmed:
18
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
Estrogen is involved in the pathogenesis of breast and gynecological cancers. Regular use of aspirin reduces estrogen levels. The present study aimed to evaluate the effect of aspirin on estrogen levels in postmenopausal women. This double-blind, placebo-controlled parallel-group trial was conducted on postmenopausal women referred to an outpatient clinic at a women's hospital in Tehran. Volunteers were randomly assigned to receive aspirin 100 mg/day or placebo for 6 weeks. Estradiol, sex hormone-binding globulin (SHBG), and testosterone levels at baseline and at the end of the intervention were measured by ELISA. Data were analyzed using SPSS 20, Kolmogorov-Smirnov test, independent samples t-test, and Mann-Whitney U test. Twenty-seven and 28 participants were finally analyzed in the aspirin and placebo groups, respectively. There was no significant difference between the two groups in body mass index (BMI), age, or menopausal years. There was a statistically significant difference (p = 0.002) in the amount of change in estradiol levels of the intervention group (median=- 3.5 pg/ml) compared to the control group (median=1.5 pg/ml). In contrast, there were no significant differences between the two groups regarding testosterone and SHBG levels (p = 0.58, p = 0.32). Since low doses of aspirin may decrease estradiol levels, it could be considered a promising adjunctive therapeutic candidate in postmenopausal women to decrease BC incidence. However, further studies with larger sample sizes, measurements of estrogen levels and its related compounds in different time points accompanied by long-term follow-ups are needed to better elucidate the potential mechanisms by which nonsteroidal anti-inflammatory drugs (NSAIDs) negatively affect breast cancer. IRCT201012195397N1. Date of first registration: 03/01/2011.
Sections du résumé
BACKGROUND
Estrogen is involved in the pathogenesis of breast and gynecological cancers. Regular use of aspirin reduces estrogen levels. The present study aimed to evaluate the effect of aspirin on estrogen levels in postmenopausal women.
METHODS
This double-blind, placebo-controlled parallel-group trial was conducted on postmenopausal women referred to an outpatient clinic at a women's hospital in Tehran. Volunteers were randomly assigned to receive aspirin 100 mg/day or placebo for 6 weeks. Estradiol, sex hormone-binding globulin (SHBG), and testosterone levels at baseline and at the end of the intervention were measured by ELISA. Data were analyzed using SPSS 20, Kolmogorov-Smirnov test, independent samples t-test, and Mann-Whitney U test.
RESULTS
Twenty-seven and 28 participants were finally analyzed in the aspirin and placebo groups, respectively. There was no significant difference between the two groups in body mass index (BMI), age, or menopausal years. There was a statistically significant difference (p = 0.002) in the amount of change in estradiol levels of the intervention group (median=- 3.5 pg/ml) compared to the control group (median=1.5 pg/ml). In contrast, there were no significant differences between the two groups regarding testosterone and SHBG levels (p = 0.58, p = 0.32).
CONCLUSIONS
Since low doses of aspirin may decrease estradiol levels, it could be considered a promising adjunctive therapeutic candidate in postmenopausal women to decrease BC incidence. However, further studies with larger sample sizes, measurements of estrogen levels and its related compounds in different time points accompanied by long-term follow-ups are needed to better elucidate the potential mechanisms by which nonsteroidal anti-inflammatory drugs (NSAIDs) negatively affect breast cancer.
TRIAL REGISTRATION
IRCT201012195397N1. Date of first registration: 03/01/2011.
Identifiants
pubmed: 35581629
doi: 10.1186/s40360-022-00571-9
pii: 10.1186/s40360-022-00571-9
pmc: PMC9116012
doi:
Substances chimiques
Estrogens
0
Testosterone
3XMK78S47O
Estradiol
4TI98Z838E
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
31Informations de copyright
© 2022. The Author(s).
Références
Breast Cancer Res. 2006;8(6):R71
pubmed: 17181859
J Clin Endocrinol Metab. 2017 May 1;102(5):1692-1701
pubmed: 28323914
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Taiwan J Obstet Gynecol. 2019 Mar;58(2):255-260
pubmed: 30910149
Ann Oncol. 2019 Feb 1;30(2):310-316
pubmed: 30566587
J Natl Cancer Inst. 2002 Apr 17;94(8):606-16
pubmed: 11959894
Prostaglandins Other Lipid Mediat. 2006 Oct;81(1-2):55-70
pubmed: 16997132
Br J Cancer. 2008 Mar 11;98(5):989-91
pubmed: 18268496
Cancer Prev Res (Phila). 2020 Nov;13(11):967-976
pubmed: 32718942
J Clin Oncol. 2012 Oct 1;30(28):3468-77
pubmed: 22927520
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):680-7
pubmed: 18349287
BMC Cancer. 2015 Dec 16;15:960
pubmed: 26673874
Br J Cancer. 2011 Oct 11;105(8):1107-13
pubmed: 21847126
Vasc Med. 2018 Jun;23(3):201-211
pubmed: 29629844
J Exp Clin Cancer Res. 2021 Aug 17;40(1):257
pubmed: 34404424
Oncol Rep. 2005 Apr;13(4):559-83
pubmed: 15756426
J Natl Cancer Inst. 2008 Oct 15;100(20):1439-47
pubmed: 18840819
Eur J Cancer Prev. 2015 Sep;24(5):416-21
pubmed: 25380191
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):250-5
pubmed: 17049846
Breast Cancer Res. 2013 Apr 22;15(2):R34
pubmed: 23607871
Oncotarget. 2017 Jun 20;8(25):40389-40401
pubmed: 28418881
Medicine (Baltimore). 2021 Aug 20;100(33):e26870
pubmed: 34414938
Breast Cancer Res Treat. 2015 Jan;149(2):525-36
pubmed: 25589172
Br J Cancer. 2011 Aug 23;105(5):709-22
pubmed: 21772329
Cancer Prev Res (Phila). 2014 Sep;7(9):906-12
pubmed: 24924486
Epidemiology. 2016 Jul;27(4):586-93
pubmed: 27007644
Breast Cancer Res Treat. 2008 Mar;108(2):217-31
pubmed: 18297397
J Surg Res. 2018 Oct;230:71-79
pubmed: 30100043
Breast Cancer Res Treat. 2008 Jun;109(3):533-43
pubmed: 17674199
Int J Mol Sci. 2021 May 30;22(11):
pubmed: 34070921
Clin Breast Cancer. 2021 Dec;21(6):552-565
pubmed: 33741292
Ecancermedicalscience. 2021 Jul 02;15:1258
pubmed: 34567243
Oncotarget. 2017 Jan 24;8(4):6003-6012
pubmed: 27999206
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1033-41
pubmed: 20332258
BMC Cancer. 2018 Mar 13;18(1):288
pubmed: 29534696